Gilead Sciences Inc at Barclays Global Healthcare Conference Transcript
Good afternoon, and welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, covering U.S. Biopharma. I am pleased to welcome Gilead Sciences to the stage. Joining us from the company, Andy Dickinson, CFO. Andy, you're going to make some opening comments, and then we'll launch in the Q&A.
Great. Thanks. Thank you for having us, and thanks for joining the presentation. Look, at a high level, I'd say it's an exciting period for Gilead. We're moving into kind of the second stage of the restructuring expansion of the company. We have a number of growth opportunities, and we expect accelerating growth through the end of the decade. So as most of you know, we have the world's largest HIV business, stable, growing, long-term patent protection and a number of product launches that are coming between now and the end of the decade that should drive additional growth.
We have the world's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |